Nedaplatin

Overview

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than Cisplatin but has proven equally effective. It was approved for use in Japan in 1995.

Indication

Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers .

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery	2025/07/01	NCT07046221	Not Applicable	Not yet recruiting	Fujian Cancer Hospital
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma	2025/06/13	NCT07019181	Phase 2	Not yet recruiting	The First Affiliated Hospital of Xiamen University
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC	2024/07/18	NCT06508229	Phase 2	Not yet recruiting	Harbin Medical University
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma	2023/12/14	NCT06170697	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC	2023/10/26	NCT06102395	Phase 3	Recruiting	Beijing Tongren Hospital
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma	2022/08/25	NCT05515315	Phase 2	Recruiting	Fuzhou General Hospital
Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma	2021/09/09	NCT05039606	Phase 2	Not yet recruiting	Guiyang Medical University
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	2021/04/14	NCT04844385	Phase 2	Active, not recruiting	Sun Yat-sen University
Nedaplatin in Treatment for Nasopharyngeal Carcinoma	2021/04/08	NCT04834206	Phase 2	Completed	Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma	2020/06/18	NCT04437329	Phase 3	Recruiting	Affiliated Cancer Hospital & Institute of Guangzhou Medical University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Breakthrough Immunotherapy Response in Rare Lung Adenosquamous Carcinoma with Multiple Driver Mutations

3 months ago

A 63-year-old patient with advanced lung adenosquamous carcinoma harboring concurrent KRAS G12C, BRAF, PIK3CA, and FLT1 mutations achieved complete remission with tislelizumab plus chemotherapy, maintaining progression-free survival exceeding 46.5 months.

Immunochemotherapy Shows Promise for Borderline Resectable Esophageal Cancer Conversion Surgery

10 months ago

A retrospective study of 40 patients with borderline resectable esophageal squamous cell carcinoma demonstrated that PD-1 inhibitors combined with chemotherapy achieved a 67.5% conversion surgery rate and 57.5% R0 resection rate.

Neoadjuvant Immunochemotherapy Shows Promise for Early-Stage Small Cell Lung Cancer Surgery

3 years ago

A retrospective study of 19 patients with stage I-IIIA small cell lung cancer demonstrated that neoadjuvant immunotherapy combined with chemotherapy achieved an 84.2% objective response rate and enabled surgery in 52.6% of patients.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access